RecruitingNot applicableNCT06041620

Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells

Studying Thalassemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Principal Investigator
Jun Shi, PhD
Institute of Hematology & Blood Diseases Hospital, China
Intervention
VGB-Ex01(biological)
Enrollment
2 enrolled
Eligibility
3-35 years · All sexes
Timeline
20232026

Study locations (1)

Collaborators

Shanghai Vitalgen BioPharma Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06041620 on ClinicalTrials.gov

Other trials for Thalassemia

Additional recruiting or active studies for the same condition.

See all trials for Thalassemia

← Back to all trials